That's very good.
I'm not sure, Deputy Minister, if you're prepared to be even more explicit than I would be.
One example is having a more agile regulatory world. During COVID-19, we were able to streamline the regulations for drug approvals and clinical trials. We've been able to work with companies that are now investing strongly in Canada to invest even more in research and development. That is absolutely essential to reduce the cost and increase the availability of drugs. As you said, it's a balance. We need the two. We need drugs to be affordable, but we also need drugs to be developed and accessible to those who need them.
Through the strategic fund for innovation and the strategic fund for sciences, we're making parallel and incremental investments in the value of science and, equally importantly, in the importance of scientists in building a world, society and country in which people have access to not only the drugs of now but also the drugs of the future.